Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation
NCT07739888
·
clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
2500
Enrollment
INDUSTRY
Sponsor class
Conditions
Atrial Fibrillation (AF)
Interventions
BIOLOGICAL:
Abelacimab
Sponsor
Novartis Pharmaceuticals